Differential effects of antipsychotic and propsychotic drugs on prepulse inhibition and locomotor activity in Roman high- (RHA) and low-avoidance (RLA) rats.
Animal models with predictive and construct validity are necessary for developing novel and efficient therapeutics for psychiatric disorders.



We have carried out a pharmacological characterization of the Roman high- (RHA-I) and low-avoidance (RLA-I) rat strains with different acutely administered propsychotic (DOI, MK-801) and antipsychotic drugs (haloperidol, clozapine), as well as apomorphine, on prepulse inhibition (PPI) of startle and locomotor activity (activity cages).



RHA-I rats display a consistent deficit of PPI compared with RLA-I rats. The typical antipsychotic haloperidol (dopamine D2 receptor antagonist) reversed the PPI deficit characteristic of RHA-I rats (in particular at 65 and 70 dB prepulse intensities) and reduced locomotion in both strains. The atypical antipsychotic clozapine (serotonin/dopamine receptor antagonist) did not affect PPI in either strain, but decreased locomotion in a dose-dependent manner in both rat strains. The mixed dopamine D1/D2 agonist, apomorphine, at the dose of 0.05 mg/kg, decreased PPI in RHA-I, but not RLA-I rats. The hallucinogen drug DOI (5-HT2A agonist; 0.1-1.0 mg/kg) disrupted PPI in RLA-I rats in a dose-dependent manner at the 70 dB prepulse intensity, while in RHA-I rats, only the 0.5 mg/kg dose impaired PPI at the 80 dB prepulse intensity. DOI slightly decreased locomotion in both strains. Finally, clozapine attenuated the PPI impairment induced by the NMDA receptor antagonist MK-801 only in RLA-I rats.



These results add experimental evidence to the view that RHA-I rats represent a model with predictive and construct validity of some dopamine and 5-HT2A receptor-related features of schizophrenia.
Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Ignasi
I
Oliveras
Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Ana
A
Sánchez-González
Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Daniel
D
Sampedro-Viana
Department of Life and Environmental Sciences, Section of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, 09124, Cagliari, Italy.
Maria Antonietta
MA
Piludu
Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Cristóbal
C
Río-Alamos
Department of Life and Environmental Sciences, Section of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, 09124, Cagliari, Italy.
Osvaldo
O
Giorgi
Department of Life and Environmental Sciences, Section of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, 09124, Cagliari, Italy.
Maria G
MG
Corda
Research Laboratory for Stereology and Neuroscience, Bispebjerg and Frederiksberg Hospitals, Copenhagen, Denmark.
Susana
S
Aznar
Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, Virginia, 23298, USA.
Javier
J
González-Maeso
Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Cristina
C
Gerbolés
Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Gloria
G
Blázquez
Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Toni
T
Cañete
Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
Adolf
A
Tobeña
Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain. albert.fernandez.teruel@uab.cat.
Alberto
A
Fernández-Teruel
D000662:Amphetamines / Q000494:pharmacology*; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000494:pharmacology; D001362:Avoidance Learning; D003024:Clozapine / Q000494:pharmacology; D016291:Dizocilpine Maleate / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D065808:Prepulse Inhibition / Q000187:drug effects*; D051381:Rats; D044402:Receptor, Serotonin, 5-HT2A; D013216:Reflex, Startle / Q000187:drug effects*; D012559:Schizophrenia; D058826:Serotonin 5-HT2 Receptor Agonists / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology
D000662:Amphetamines; D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D018492:Dopamine Antagonists; D018691:Excitatory Amino Acid Antagonists; D044402:Receptor, Serotonin, 5-HT2A; D058826:Serotonin 5-HT2 Receptor Agonists; D012702:Serotonin Antagonists; D016291:Dizocilpine Maleate; D003024:Clozapine; D006220:Haloperidol; D001058:Apomorphine; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine
Activity; Antipsychotic drugs; Genetically based rat model; Predictive validity; Prepulse inhibition; Propsychotic drugs; Roman high- and low-avoidance rats; Schizophrenia